HomeCompareSEMRX vs MRK

SEMRX vs MRK: Dividend Comparison 2026

SEMRX yields 5.80% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $1.4K in total portfolio value· pulled ahead in Year 7
10 years
SEMRX
SEMRX
● Live price
5.80%
Share price
$9.51
Annual div
$0.55
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.3K
Annual income
$839.89
Full SEMRX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — SEMRX vs MRK

📍 MRK pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSEMRXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SEMRX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SEMRX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SEMRX
Annual income on $10K today (after 15% tax)
$493.11/yr
After 10yr DRIP, annual income (after tax)
$713.91/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $93.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SEMRX + MRK for your $10,000?

SEMRX: 50%MRK: 50%
100% MRK50/50100% SEMRX
Portfolio after 10yr
$30.0K
Annual income
$895.09/yr
Blended yield
2.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SEMRX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SEMRX buys
0
MRK buys
0
No recent congressional trades found for SEMRX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSEMRXMRK
Forward yield5.80%3.25%
Annual dividend / share$0.55$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$29.3K$30.7K
Annual income after 10y$839.89$950.29
Total dividends collected$7.1K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SEMRX vs MRK ($10,000, DRIP)

YearSEMRX PortfolioSEMRX Income/yrMRK PortfolioMRK Income/yrGap
1$11,280$580.13$11,192$351.54+$88.00SEMRX
2$12,681$611.58$12,524$392.70+$157.00SEMRX
3$14,212$642.57$14,015$438.65+$197.00SEMRX
4$15,879$673.00$15,682$489.96+$197.00SEMRX
5$17,694$702.78$17,547$547.23+$147.00SEMRX
6$19,664$731.85$19,632$611.16+$32.00SEMRX
7← crossover$21,801$760.14$21,963$682.53$162.00MRK
8$24,114$787.60$24,571$762.18$457.00MRK
9$26,617$814.20$27,486$851.08$869.00MRK
10$29,320$839.89$30,745$950.29$1.4KMRK

SEMRX vs MRK: Complete Analysis 2026

SEMRXStock

The fund invests primarily in investment-grade debt securities of domestic entities. The Adviser will primarily sell securities short for the purposes of managing certain risks (primarily interest rate and/or yield spread risk) associated with its long positions or for capturing differences in value between two securities, and not for the purpose of forecasting the market's direction.

Full SEMRX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this SEMRX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SEMRX vs SCHDSEMRX vs JEPISEMRX vs OSEMRX vs KOSEMRX vs MAINSEMRX vs JNJSEMRX vs ABBVSEMRX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.